Dme Capital Management, LP Gain Therapeutics, Inc. Call Options Transaction History
Dme Capital Management, LP
- $2.18 Trillion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding GANX
# of Institutions
32Shares Held
2.32MCall Options Held
22.2KPut Options Held
16K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$682,5550.1% of portfolio
-
Royal Bank Of Canada Toronto, A6249KShares$288,2600.0% of portfolio
-
Geode Capital Management, LLC Boston, MA177KShares$205,4250.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$142,6800.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA119KShares$138,4620.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $13.8M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...